Cargando…
Ustekinumab for steroid-refractory pancolitis in a biologically naive child: A case report and literature review
Ustekinumab is not recommended for the treatment of children with inflammatory bowel disease, but its off-label use is increasing despite a lack of pediatric pharmacokinetic data. The purpose of this review is to evaluate the therapeutic effects of Ustekinumab on children with inflammatory bowel dis...
Autor principal: | Alhalabi, Marouf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981362/ https://www.ncbi.nlm.nih.gov/pubmed/36862878 http://dx.doi.org/10.1097/MD.0000000000033061 |
Ejemplares similares
-
Subcutaneous golimumab induced and maintained clinical response in a child with a biological-experienced steroid-refractory flare of ulcerative colitis: A case report
por: Alhalabi, Marouf, et al.
Publicado: (2021) -
Mortality and risk factors associated with peptic ulcer bleeding among adult inpatients of Damascus Hospital, Syria: A cross-sectional study
por: Alhalabi, Marouf Mouhammad
Publicado: (2023) -
SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report
por: Alhalabi, Marouf, et al.
Publicado: (2022) -
Ustekinumab is effective against ulcerative colitis with intestinal stenosis: A case report
por: Liu, Ailing, et al.
Publicado: (2022) -
Subcutaneous golimumab to treat a biological naïve chronically active ulcerative colitis child. A case report
por: Alhalabi, Marouf M., et al.
Publicado: (2022)